Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
This Month's Exclusive Content Is Abbott's January Pullback a Good Time to Buy? Author: Thomas Hughes. Posted: 1/24/2026. 
In Brief - Abbott Laboratories’ January pullback looks driven more by sentiment than fundamentals, putting shares back near a prior accumulation zone.
- Quarterly results showed solid sales growth, improving margins, and faster adjusted earnings growth despite a revenue miss.
- A long dividend-growth track record and potential upside implied by analyst targets underpin the bullish rebound case.
Abbott Laboratories' (NYSE: ABT) January 2026 price pullback has made the stock look more attractively valued. The move—driven more by market angst and fear than by any real business weakness—appears to be a knee-jerk overreaction that pushes the shares back into a buy zone. 
A former hedge fund manager known for cutting through market noise is briefly opening access to his flagship trading strategy. In a short demo, he explains how his "One Ticker" approach works — and how readers can access the full service for a year at a steep discount. Watch the brief demo here The zone in question aligns with market action from 2022–2024, when Abbott was recovering from a post-COVID revenue contraction and institutions were actively accumulating the stock. Abbott Laboratories Growth Accelerates At worst, Abbott Laboratories' Q4 results and guidance missed a few expectations. Still, revenue of $11.46 billion was up 4.5% year over year, margins improved, and adjusted earnings accelerated. Revenue growth came in several hundred basis points below hopes, but margin strength helped offset the shortfall: adjusted earnings per share (EPS) rose about 12%, slightly above consensus. By segment, the results highlighted the strength of Abbott's diversified healthcare portfolio. The Nutrition and Diagnostics segments contracted—Nutrition declined nearly 9%—but solid growth in Established Pharmaceuticals and Med Tech more than offset those drops. Established Pharmaceuticals grew roughly 9%, driven by generics and emerging markets, while Med Tech expanded about 12.3%, showing broad strength across sub-segments. Margin performance was also positive, coming in slightly ahead of analyst forecasts. A shift in product mix toward higher-margin Med Tech, reduced COVID-19-related sales, and operational improvements lifted profitability. Looking ahead, Abbott expects earnings to grow another ~10% in 2026, outpacing revenue growth and supporting its capital-return plans. Abbott's capital returns are central to the investment case. The company is a Dividend King, having raised its payout annually for more than 50 years, and it appears positioned to continue that trend. Currently the stock yields about 2.5% after the pullback, and Abbott pays out under 50% of earnings on a consensus basis—leaving room in cash flow for share buybacks, which help mitigate dilution from share-based compensation. Analysts Point to Robust Rebound in Abbott Laboratories Stock Some analysts flagged the revenue miss, but there were no immediate, material rating or price-target cuts the morning of the release. The prevailing view is that this is a fundamentally healthy company that can continue returning capital while reinvesting in growth, with a meaningful growth runway. The consensus share price target, per MarketBeat, implies the stock could rebound as much as ~30%, possibly reaching new all-time highs, while even the lower-end targets suggest upside versus current levels. Key catalysts include an expanding Med Tech portfolio, AI integration across operations and products, margin expansion, and targeted acquisitions. The acquisition of Exact Sciences is one example of moves that expand Abbott's revenue and profit streams and broaden its product pipeline. Abbott's recent decline has been painful and could deepen, but institutions that accumulated shares throughout 2025 are likely buyers at these discounted prices. Early technical support appears in the $105–$110 range, although that level is not yet confirmed. The risk is that ABT could drift lower to the low end of the buy zone before staging a rebound—potentially testing the mid-$90s or below.
| 
